Shares of medical device manufacturer Zimmer Biomet are experiencing notable downward pressure in today’s trading session. This movement follows disclosures of significant position reductions by major institutional holders during the second quarter, coupled with a reiterated bearish stance from Goldman Sachs analysts.
Mixed Institutional Activity and Analyst Caution
Recent regulatory filings reveal a wave of selling by prominent investment firms in Q2 2025. European asset manager Amundi slashed its stake by 38.7%, selling 401,103 shares, which reduces its holding to approximately 0.32% of the company. Concurrently, hedge fund Marshall Wace LLP cut its position by 28.3%, involving 98,367 shares.
This selling activity aligns with continued skepticism from Wall Street research. An analyst at Goldman Sachs has reaffirmed a ‘Sell’ rating on the equity. The market’s reaction was swift: after closing at $94.28 on Monday, the stock opened today’s session at $92.76.
However, the institutional landscape is not uniformly negative. Other substantial investors, including Gamco Investors, Dodge & Cox, and Invesco Ltd., expanded their holdings in the same quarter by margins ranging from 11.5% to 22.5%.
Should investors sell immediately? Or is it worth buying Zimmer Biomet?
Strong Fundamentals Contrast with Market Sentiment
The current cautious mood stands in sharp contrast to the company’s recently reported solid operational performance. Zimmer Biomet’s third-quarter 2025 results, released on November 5, exceeded market expectations. Earnings per share (EPS) came in at $1.90, slightly ahead of the consensus estimate of $1.88. Revenue of $2.0 billion represented a robust year-over-year increase of 9.6%.
Despite these strong underlying business metrics, the stock remains under pressure. Analyst opinions are divided; current market data shows 9 ‘Buy’ ratings, 9 ‘Hold’ ratings, and 2 ‘Sell’ recommendations. With institutional ownership nearing 89%, portfolio rebalancing by large funds has an outsized and immediate impact on the share price.
Technical Position and Forward-Looking Focus
Market participants are now likely to turn their attention to the upcoming quarterly report for confirmation of growth prospects heading into 2026. The full-year 2025 guidance projects earnings per share in the range of $8.10 to $8.30.
From a technical analysis perspective, the equity is in a challenging position. It is currently trading below its key 50-day (approximately $96.31) and 200-day (approximately $98.93) moving averages. Meanwhile, a Relative Strength Index (RSI) reading of 30.22 suggests the stock is in oversold territory. This condition could potentially set the stage for a short-term rebound once broader market sentiment stabilizes.
Ad
Zimmer Biomet Stock: Buy or Sell?! New Zimmer Biomet Analysis from February 7 delivers the answer:
The latest Zimmer Biomet figures speak for themselves: Urgent action needed for Zimmer Biomet investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Zimmer Biomet: Buy or sell? Read more here...
